Double-Drug attack on tough lung cancer mutation
Disease control
Completed
This study tests whether combining two targeted drugs, avutometinib and adagrasib, can shrink tumors in people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. Participants must have already tried a KRAS G12C inhibitor and seen their c…
Phase: PHASE1, PHASE2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC